CYP2D6基因型指导他莫昔芬剂量用于激素受体阳性转移性乳腺癌的随机II期研究
TARGET-1研究在186例日本激素受体阳性转移性乳腺癌患者中,将CYP2D6变异等位基因携带者随机分配至他莫昔芬增量组(40mg/d)或常规剂量组(20mg/d),野生型纯合子接受20mg/d。主要终点6个月无进展生存率在增量组与常规组间无显著差异(67.6% vs 66.7%)。增量组Z-内皮昔芬谷浓度显著高于常规组,但浓度与临床结局无显著相关。
要点
- CYP2D6变异等位基因携带者增量他莫昔芬至40mg/d未提高6个月PFS率。
- 增量组Z-内皮昔芬谷浓度显著高于常规组,但浓度与进展无显著相关。
- CYP2D6基因型单独不能解释他莫昔芬疗效的个体差异。
核心结论
- 在CYP2D6变异等位基因携带的激素受体阳性转移性乳腺癌患者中,增加他莫昔芬剂量未获得更高的6个月PFS率。
- CYP2D6基因型单独不能解释他莫昔芬疗效的个体差异。
研究设计与样本
- 随机、开放标签、多中心、II期研究,2012年12月至2016年7月在日本入组186例需一线他莫昔芬治疗的患者。
- CYP2D6变异等位基因杂合子(wt/V)或纯合子(V/V)随机接受他莫昔芬增量组(40mg每日)或常规剂量组(20mg每日),野生型纯合子(wt/wt)接受20mg每日。
- 主要终点为6个月无进展生存率,次要终点包括PFS及Z-内皮昔芬浓度与临床结局的相关性。
主要发现
- 184例可评估患者中,136例携带wt/V或V/V(增量组70例,常规组66例),48例为wt/wt。
- 增量组与常规组6个月PFS率无显著差异(67.6% vs 66.7%)。
- 增量组Z-内皮昔芬血清谷浓度显著高于常规组(中位89.2 nM vs 51.1 nM;P < .0001),也高于wt/wt患者(72.0 nM;P = .045)。
- 疾病进展患者与6个月无进展患者的Z-内皮昔芬浓度无显著差异(P = .43)。
临床怎么用
- 对于CYP2D6变异等位基因携带的激素受体阳性转移性乳腺癌患者,不推荐基于基因型常规增加他莫昔芬剂量至40mg/d以改善PFS。
- 他莫昔芬疗效的个体差异不能仅由CYP2D6基因型解释,需综合考虑其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether CYP2D6 genotype-guided tamoxifen dosing in patients with hormone receptor-positive metastatic breast cancer could have an impact on the clinical outcome. METHODS: Patients who needed first-line tamoxifen therapy were enrolled. Based on individual CYP2D6 genotype, patients heterozygous (wild type [wt]/variant [V]) or homozygous (V/V) for variant alleles of decreased or no function were randomly assigned to receive tamoxifen at an increased dose (ID arm; 40 mg daily) or regular dose (RD arm; 20 mg daily), and patients homozygous for wild-type alleles (wt/wt) received tamoxifen at 20 mg daily. The primary endpoint was the progression-free survival (PFS) rate at 6 months. The secondary endpoints included PFS and correlation of Z-endoxifen concentration with clinical outcomes. RESULTS: Between December 2012 and July 2016, 186 patients were enrolled in Japan. Of 184 evaluable patients, 136 carried wt/V or V/V (ID arm, 70; RD arm, 66), and 48 carried wt/wt. PFS rates at 6 months were not significantly different between the ID and RD arms (67.6% v 66.7%). The serum trough concentrations of Z-endoxifen in the ID arm were significantly higher than those in the RD arm (median, 89.2 nM v 51.1 nM; P < .0001) and were also higher compared with wt/wt patients (72.0 nM; P = .045). No significant difference in Z-endoxifen concentrations was observed between patients with disease progression and those who were progression free at 6 months (P = .43). CONCLUSION: In patients with CYP2D6-variant alleles, increasing tamoxifen dosing did not achieve a higher PFS rate at 6 months. The CYP2D6 genotype solely cannot explain individual variability in the efficacy of tamoxifen.
引用
- Tamura K, Imamura CK, Takano T, et al. CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. J Clin Oncol. 2019. PMID: 31821071. doi:10.1200/JCO.19.01412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。